Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
So here are some takeaways on the longevity of the obesity platform: Even without GLP-1 craze they grew the business (profitably?) to a $100M run-rate in 7 months with oral weight loss medications alone We will see a flood of new GLP-1 medications enter the market and the situation will move quickly and be fluid including the introduction of oral compounds that may lead to other use-cases for Hims There is some sort of precedent that compounding certain elements like end-dosage or side effect mitigation is considered clinically necessary and therefore defensible Hims & Hers will also offer brand-name GLP-1s on platform, maybe alluding to expectations of reduction in out of pocket cost over time, or an increase in supply My unsolicited thoughts for Hims would be to take advantage of this huge surge in cash and invest it into the sustainable, growing parts of the business
(n.d.) Research Spotlight: Type 1 diabetes staging classification opens door for intervention
Book a consultation to discuss whether GHK-Cu is the right addition to your current wellness and aesthetic protocol
Their effectiveness has made them increasingly popular, but people using these medications may have questions about their long-term side effects and safety
Multiple factors related to the secretion of glucagonlike peptide1. International journal of endocrinology 2015.1 (2015): 651757
We encourage our patients to openly discuss their preferences and lifestyle needs with us, as this greatly influences the choice of medication
